10-K.Info (Beta Test) Courtesy of Short Sands, LLC | ||||||||||||||
| ||||||||||||||
|
10-K.Info (Beta Test) Courtesy of Short Sands, LLC | |||
CVS HEALTH CORP | |||
Ticker: CVS Fiscal Year: 2020 | |||
Consolidated Statements of Operations | |||
Period Ending Dec 31, 2020 10-K (Filed: Feb 16, 2021) | |||
| (In Millions) | |||
| 12 Months Ended | 12 Months Ended | 12 Months Ended | |
| Dec 31, 2020 | Dec 31, 2019 | Dec 31, 2018 | |
| Revenues: | |||
| Premiums | $ 69,364 | 63,122 | 8,184 |
| Net investment income | 798 | 1,011 | 660 |
| Total revenues | 268,706 | 256,776 | 194,579 |
| Operating costs: | |||
| Cost of products sold | 163,981 | 158,719 | 156,447 |
| Benefit costs | 55,679 | 52,529 | 6,594 |
| Goodwill impairments | 0 | 0 | 6,149 |
| Operating expenses | 35,135 | 33,541 | 21,368 |
| Total operating costs | 254,795 | 244,789 | 190,558 |
| Operating income | 13,911 | 11,987 | 4,021 |
| Interest expense | 2,907 | 3,035 | 2,619 |
| Loss on early extinguishment of debt | 1,440 | 79 | 0 |
| Other income | (206) | (124) | (4) |
| Income before income tax provision | 9,770 | 8,997 | 1,406 |
| Income tax provision | 2,569 | 2,366 | 2,002 |
| Income (loss) from continuing operations | 7,201 | 6,631 | (596) |
| Loss from discontinued operations, net of tax | (9) | 0 | 0 |
| Net income (loss) | 7,192 | 6,631 | (596) |
| Net (income) loss attributable to noncontrolling interests | (13) | 3 | 2 |
| Net income (loss) attributable to CVS Health | 7,179 | 6,634 | (594) |
| Basic earnings (loss) per share: | |||
| Income (loss) from continuing operations attributable to CVS Health (in dollars per share) | 5.49 | 5.10 | (0.57) |
| Loss from discontinued operations attributable to CVS Health (in dollars per share) | (0.01) | 0.00 | 0.00 |
| Net income (loss) attributable to CVS Health (in dollars per share) | 5.48 | 5.10 | (0.57) |
| Weighted average basic shares outstanding (in shares) | 1,309 | 1,301 | 1,044 |
| Diluted earnings (loss) per share: | |||
| Income (loss) from continuing operations attributable to CVS Health (in dollars per share) | 5.47 | 5.08 | (0.57) |
| Loss from discontinued operations attributable to CVS Health (in dollars per share) | (0.01) | 0.00 | 0.00 |
| Net income (loss) attributable to CVS Health (in dollars per share) | 5.46 | 5.08 | (0.57) |
| Weighted average diluted shares outstanding (in shares) | 1,314 | 1,305 | 1,044 |
| Dividends declared per share (in dollars per share) | 2.00 | 2.00 | 2.00 |
| Cost, Product and Service [Extensible List] | us-gaap:ProductMember | us-gaap:ProductMember | us-gaap:ProductMember |
| Product and Service | |||
| Products | |||
| Revenue from Products and Services | 190,688 | 185,236 | 183,910 |
| Services | |||
| Revenue from Products and Services | 7,856 | 7,407 | 1,825 |
10-K.Info (Beta Test) Courtesy of Short Sands, LLC | |||
CVS HEALTH CORP | |||
Ticker: CVS Fiscal Year: 2020 | |||
Consolidated Statements of Comprehensive Income (Loss) | |||
Period Ending Dec 31, 2020 10-K (Filed: Feb 16, 2021) | |||
| (In Millions, except shares in actual) | |||
| 12 Months Ended | 12 Months Ended | 12 Months Ended | |
| Dec 31, 2020 | Dec 31, 2019 | Dec 31, 2018 | |
| Net income (loss) | $ 7,192 | 6,631 | (596) |
| Other comprehensive income (loss), net of tax: | |||
| Net unrealized investment gains | 440 | 677 | 97 |
| Foreign currency translation adjustments | 3 | 162 | (29) |
| Net cash flow hedges | (31) | (33) | 330 |
| Pension and other postretirement benefits | (17) | 111 | (124) |
| Other comprehensive income (loss) | 395 | 917 | 274 |
| Comprehensive income (loss) | 7,587 | 7,548 | (322) |
| Comprehensive (income) loss attributable to noncontrolling interests | (13) | 3 | 2 |
| Comprehensive income (loss) attributable to CVS Health | 7,574 | 7,551 | (320) |
10-K.Info (Beta Test) Courtesy of Short Sands, LLC | |||
CVS HEALTH CORP | |||
Ticker: CVS Fiscal Year: 2020 | |||
Consolidated Statements of Cash Flows | |||
Period Ending Dec 31, 2020 10-K (Filed: Feb 16, 2021) | |||
| (In Millions, except shares in actual) | |||
| 12 Months Ended | 12 Months Ended | 12 Months Ended | |
| Dec 31, 2020 | Dec 31, 2019 | Dec 31, 2018 | |
| Cash flows from operating activities: | |||
| Cash receipts from customers | $ 264,327 | 248,393 | 186,519 |
| Cash paid for inventory and prescriptions dispensed by retail network pharmacies | (158,636) | (149,655) | (148,981) |
| Insurance benefits paid | (55,124) | (52,242) | (6,897) |
| Cash paid to other suppliers and employees | (29,763) | (28,932) | (17,234) |
| Interest and investment income received | 894 | 955 | 644 |
| Interest paid | (2,904) | (2,954) | (2,803) |
| Income taxes paid | (2,929) | (2,717) | (2,383) |
| Net cash provided by operating activities | 15,865 | 12,848 | 8,865 |
| Cash flows from investing activities: | |||
| Proceeds from sales and maturities of investments | 6,467 | 7,049 | 817 |
| Purchases of investments | (9,639) | (7,534) | (692) |
| Purchases of property and equipment | (2,437) | (2,457) | (2,037) |
| Proceeds from sale-leaseback transactions | 101 | 5 | 0 |
| Acquisitions (net of cash acquired) | (866) | (444) | (42,226) |
| Proceeds from sale of subsidiaries and other assets | 840 | 0 | 832 |
| Other | 0 | 42 | 21 |
| Net cash used in investing activities | (5,534) | (3,339) | (43,285) |
| Cash flows from financing activities: | |||
| Net repayments of short-term debt | 0 | (720) | (556) |
| Proceeds from issuance of long-term debt | 9,958 | 3,736 | 44,343 |
| Repayments of long-term debt | (15,631) | (8,336) | (5,522) |
| Derivative settlements | (7) | (25) | 446 |
| Dividends paid | (2,624) | (2,603) | (2,038) |
| Proceeds from exercise of stock options | 264 | 210 | 242 |
| Payments for taxes related to net share settlement of equity awards | (88) | (112) | (97) |
| Other | (27) | 0 | 1 |
| Net cash provided by (used in) financing activities | (8,155) | (7,850) | 36,819 |
| Effect of exchange rate changes on cash, cash equivalents and restricted cash | 0 | 0 | (4) |
| Net increase in cash, cash equivalents and restricted cash | 2,176 | 1,659 | 2,395 |
| Cash, cash equivalents and restricted cash at the beginning of the period | 5,954 | 4,295 | |
| Cash, cash equivalents and restricted cash at the end of the period | 8,130 | 5,954 | 4,295 |
| Reconciliation of net income (loss) to net cash provided by operating activities: | |||
| Net income (loss) | 7,192 | 6,631 | (596) |
| Reconciliation of net income (loss) to net cash provided by operating activities: | |||
| Depreciation and amortization | 4,441 | 4,371 | 2,718 |
| Goodwill impairments | 0 | 0 | 6,149 |
| Stock-based compensation | 400 | 453 | 280 |
| (Gain) loss on sale of subsidiaries | (269) | 205 | 86 |
| Loss on early extinguishment of debt | 1,440 | 79 | 0 |
| Deferred income taxes | (570) | (654) | 87 |
| Other noncash items | 72 | 264 | 253 |
| Change in operating assets and liabilities, net of effects from acquisitions: | |||
| Accounts receivable, net | (1,510) | (2,158) | (1,139) |
| Inventories | (973) | (1,075) | (1,153) |
| Other assets | 364 | (614) | (3) |
| Accounts payable and pharmacy claims and discounts payable | 2,769 | 3,550 | 2,329 |
| Health care costs payable and other insurance liabilities | (231) | 320 | (311) |
| Other liabilities | 2,740 | 1,476 | 165 |
| Net cash provided by operating activities | 15,865 | 12,848 | 8,865 |
10-K.Info (Beta Test) Courtesy of Short Sands, LLC | ||
CVS HEALTH CORP | ||
Ticker: CVS Fiscal Year: 2020 | ||
Consolidated Balance Sheets | ||
Period Ending Dec 31, 2020 10-K (Filed: Feb 16, 2021) | ||
| (In Millions, except shares in actual) | ||
| As of | As of | |
| Dec 31, 2020 | Dec 31, 2019 | |
| Assets: | ||
| Cash and cash equivalents | $ 7,854 | 5,683 |
| Investments | 3,000 | 2,373 |
| Accounts receivable, net | 21,742 | 19,617 |
| Inventories | 18,496 | 17,516 |
| Other current assets | 5,277 | 5,113 |
| Total current assets | 56,369 | 50,302 |
| Long-term investments | 20,812 | 17,314 |
| Property and equipment, net | 12,606 | 12,044 |
| Operating lease right-of-use assets | 20,729 | 20,860 |
| Goodwill | 79,552 | 79,749 |
| Intangible assets, net | 31,142 | 33,121 |
| Separate accounts assets | 4,881 | 4,459 |
| Other assets | 4,624 | 4,600 |
| Total assets | 230,715 | 222,449 |
| Liabilities: | ||
| Accounts payable | 11,138 | 10,492 |
| Pharmacy claims and discounts payable | 15,795 | 13,601 |
| Health care costs payable | 7,936 | 6,879 |
| Policyholders funds | 4,270 | 2,991 |
| Accrued expenses | 14,243 | 12,133 |
| Other insurance liabilities | 1,557 | 1,830 |
| Current portion of operating lease liabilities | 1,638 | 1,596 |
| Current portion of long-term debt | 5,440 | 3,781 |
| Total current liabilities | 62,017 | 53,303 |
| Long-term operating lease liabilities | 18,757 | 18,926 |
| Long-term debt | 59,207 | 64,699 |
| Deferred income taxes | 6,794 | 7,294 |
| Separate accounts liabilities | 4,881 | 4,459 |
| Other long-term insurance liabilities | 7,007 | 7,436 |
| Other long-term liabilities | 2,351 | 2,162 |
| Total liabilities | 161,014 | 158,279 |
| Commitments and contingencies (Note 16) | ||
| Shareholders equity: | ||
| Preferred stock, par value $0.01: 0.1 shares authorized; none issued or outstanding | 0 | 0 |
| Common stock, par value $0.01: 3,200 shares authorized; 1,733 shares issued and 1,310 shares outstanding at December 31, 2020 and 1,727 shares issued and 1,302 shares outstanding at December 31, 2019 and capital surplus | 46,513 | 45,972 |
| Treasury stock, at cost: 423 and 425 shares at December 31, 2020 and 2019 | (28,178) | (28,235) |
| Retained earnings | 49,640 | 45,108 |
| Accumulated other comprehensive income | 1,414 | 1,019 |
| Total CVS Health shareholders equity | 69,389 | 63,864 |
| Noncontrolling interests | 312 | 306 |
| Total shareholders equity | 69,701 | 64,170 |
| Total liabilities and shareholders equity | 230,715 | 222,449 |
| External Links | |
| CVS HEALTH CORP (CVS) Fiscal Year 2020 | |
| Statements of 10-K in Excel | https://www.sec.gov/.../Financial.xlxs |
| Complete 10-K in HTML | https://www.sec.gov/.../10-K.html |
| Complete 10-K in XBRL | https://www.sec.gov/.../10-K-xbrl.zip |